news, journals and articles from all over the world.
A large multicenter, randomized clinical trial revealed no difference in the risk of endotracheal intubation requirement at 30 days between awake prone positioning and standard positioning for patients with COVID-19 who suffered from acute hypoxemic respiratory failure, according to research published in JAMA by researchers at UTHealth Houston.
Younger adults living in the U.S. are less likely to be screened for colorectal cancer than older U.S. adults, despite now being eligible under new screening guidelines, and face greater disparities than older U.S. adults who are eligible for screening, according to research from UTHealth Houston.
People who received at least one influenza vaccine were 40% less likely than their non-vaccinated peers to develop Alzheimer’s disease over the course of four years, according to a new study from UTHealth Houston.
Anne Briggs always longed to be a mom.
But after having no menstrual cycle for over a decade, she knew when she married her husband Mark in 2020 that conceiving a child naturally would be unlikely.
Patients diagnosed with cancer more than one year ago and those not receiving active treatment were no more vulnerable to worse COVID-19 outcomes than patients without cancer, according to a new study led by UTHealth Houston.
UTHealth Houston’s Movement Disorders and Neurodegenerative Diseases Fellowship Training Program (UTMOVE fellowship program) has been chosen by The Michael J. Fox Foundation for Parkinson’s Research (MJFF) as one of eight international academic centers to train a new movement disorder clinician-researcher — a neurologist with additional training and expertise in diagnosing and treating Parkinson’s and related diseases — as part of the Edmond J. Safra Fellowship in Movement Disorders Class of 2025.
Children previously infected with COVID-19 develop natural circulating antibodies that last for at least seven months, according to a new study led by researchers at UTHealth Houston.
It’s no secret that vitamin D is critical to balancing many areas of health. But from pediatric broken bones to cluster headaches, physicians and scientists at The University of Texas Health Science Center at Houston (UTHealth Houston) are still learning just how powerful the so-called “sunshine vitamin” is.
Her scientific leadership in the laboratory studying sex differences in stroke severity and outcomes is among the reasons why Louise McCullough, MD, PhD, received the 2021 C. Miller Fisher, MD Neuroscience Visionary Award from the American Heart Association/American Stroke Association (AHA/ASA).
In an odd twist of fate, 57-year-old Burnett Langley discovered after his four-vessel coronary artery bypass that his surgeon, Steven Eisenberg, MD, performed the same procedure on his mother, Monnie, exactly 10 years earlier.
Mexico City resident Alejandra Gaehd, who has long suffered from tonic-clonic seizures, has been able to return to a normal life following a minimally invasive procedure performed by UTHealth Houston neurosurgeon Nitin Tandon, MD.
A preclinical development core where researchers can test the effectiveness of large molecule drug candidates for novel cancer treatments, led by Qingyun Liu, PhD, has been awarded a nearly $4 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT).
Ischemic stroke patients treated on a mobile stroke unit (MSU) received anti-clot medication faster and ended up with less disability at 90 days, according to a study published today in the New England Journal of Medicine led by researchers at UTHealth Houston and Memorial Hermann-Texas Medical Center.
Infants whose mothers were obese during pregnancy may have a heightened risk of developing colorectal cancer later in life, according to new research led by public health experts at The University of Texas Health Science Center at Houston (UTHealth).
MTX110 is a new formulation of panobinostat, a chemotherapy drug that has shown promise in laboratory models of medulloblastoma, the most common malignant brain tumor in children. Now, MTX110 is the focus of a novel trial that places the therapy directly into the fourth ventricle of the brain to treat patients with recurrent medulloblastoma.
English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
Urdu